predator eyes pharmaxis - afr, page-11

The company does not know anything "other than what is in the report".... so they know something.
Personally I think they should not sell.... way to much value to let it go cheaply at this stage.
Good to see they took the opportunity to remind the market of upcoming value drivers......
Should see some goo movement up in coming days / months....

However, the Company does note the following:
? The September 2012 Quarterly Report to Shareholders is due to be released
to the market on 10 October 2012
? The quarterly investor conference call is scheduled for 11 October 2012
? The Company’s product Bronchitol® is to be the subject of several
presentations at this week’s North American Cystic Fibrosis Conference
? Updates on several European pricing applications are expected over the next
two months, although the specific timing is not known at this time by the
Company
? As discussed in previous quarterly reports, Pharmaxis continues to explore
all available options to capture the full value of its US new drug application
for Bronchitol.